PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.

Authors

null

Maria Vidal

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Maria Vidal , Lorena De La Pena , Mafalda Oliveira , Javier Cortes , Antonio Llombart , Aleix Prat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS665)

DOI

10.1200/jco.2013.31.15_suppl.tps665

Abstract #

TPS665

Poster Bd #

17A

Abstract Disclosures

Similar Posters

First Author: Christian F. Singer

First Author: Sandra M. Swain

First Author: Ning Liao